(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Jury says Johnson & Johnson owes $40 million to 2 cancer patients who used talcum powders - 2Finding the Force of Mentorship: Self-awareness Through Direction
- 3This Week In Space podcast: Episode 204 — A New NASA
- 4Striking American and European television Projects: A Survey
- 5Great DSLR Cameras for Photography Devotees
- Figure out How to Take part in Open Conversations Around 5G Pinnacles
- Vacuum Cleaners That Are Not difficult To Use For Home
- Figure out how to Use Your Brain research Degree in the Gig Market
- Obamacare enrollment declines as US subsidies expire
- Fact Check: Israeli Channel 13, Al Jazeera Did NOT Confirm Hezbollah Captured All Or Part Of Kiryat Shmona
- OECD: Iran war dampening global growth
- The most effective method to Boost Eco-friendliness in Your Volvo XC40
- 'Hero' who wrestled gun from Bondi shooter named as Ahmed al Ahmed
- Tracking down the Right Equilibrium: Charges versus Personal Costs in Senior Protection.
